{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:03:02Z","timestamp":1783450982446,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Specialized Program of Research Excellence (SPORE) in Lung Cancer","award":["P50CA70907"],"award-info":[{"award-number":["P50CA70907"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP160668"],"award-info":[{"award-number":["RP160668"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>CD73 is a membrane-bound enzyme crucial in adenosine generation. The adenosinergic pathway plays a critical role in immunosuppression and in anti-tumor effects of immune checkpoint inhibitors (ICI). Here, we interrogated CD73 expression in a richly annotated cohort of human lung adenocarcinoma (LUAD) and its association with clinicopathological, immune, and molecular features to better understand the role of this immune marker in LUAD pathobiology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Protein expression of CD73 was evaluated by immunohistochemistry in 106 archived LUADs from patients that underwent surgical treatment without neoadjuvant therapy. Total CD73 (T\u2009+) was calculated as the average of luminal (L\u2009+) and basolateral (BL\u2009+) percentage membrane expression scores for each LUAD and was used to classify tumors into three groups based on the extent of T CD73 expression (high, low, and negative).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>CD73<\/jats:italic> expression was significantly and progressively increased across normal-appearing lung tissue, adenomatous atypical hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, and LUAD. In LUAD, BL CD73 expression was associated with an increase in PD-L1 expression in tumor cells and increase of tumor-associated immune cells. Stratification of LUADs based on T CD73 extent also revealed that tumors with high expression of this enzyme overall exhibited significantly elevated immune infiltration and PD-L1 protein expression. Immune profiling demonstrated that T-cell inflammation and adenosine signatures were significantly higher in CD73-expressing lung adenocarcinomas relative to those lacking CD73.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study suggests that higher CD73 expression is associated with an overall augmented host immune response, suggesting potential implications in the immune pathobiology of early stage lung adenocarcinoma. Our findings warrant further studies to explore the role of CD73 in immunotherapeutic response of LUAD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-020-02820-4","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T06:04:25Z","timestamp":1610085865000},"page":"1965-1976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma"],"prefix":"10.1007","volume":"70","author":[{"given":"Pedro","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Solorzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Dejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzifa Y.","family":"Douse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle Gregory","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annikka","family":"Weissferdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Parra-Cuentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cascone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Sepesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Kalhor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Vaporciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Jack","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humam","family":"Kadara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-630X","authenticated-orcid":false,"given":"Luisa Maren","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"2820_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"2820_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"2820_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"2820_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"2820_CR5","doi-asserted-by":"publisher","first-page":"2017770412","DOI":"10.1200\/JCO.2017.77.0412","volume":"003","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D et al (2018) Five-year follow-up of Nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209\u2013003 study. J Clin Oncol 003:2017770412. https:\/\/doi.org\/10.1200\/JCO.2017.77.0412","journal-title":"J Clin Oncol"},{"key":"2820_CR6","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN et al (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 378:1976\u20131986. https:\/\/doi.org\/10.1056\/NEJMoa1716078","journal-title":"N Engl J Med"},{"key":"2820_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"2820_CR8","doi-asserted-by":"publisher","first-page":"460654","DOI":"10.1155\/2014\/460654","volume":"2014","author":"ZW Gao","year":"2014","unstructured":"Gao ZW, Dong K, Zhang HZ (2014) The roles of CD73 in cancer. Biomed Res Int 2014:460654. https:\/\/doi.org\/10.1155\/2014\/460654","journal-title":"Biomed Res Int"},{"key":"2820_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","journal-title":"Nat Rev Clin Oncol"},{"key":"2820_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14:717\u2013734. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101","journal-title":"Nat Rev Clin Oncol"},{"key":"2820_CR11","doi-asserted-by":"publisher","first-page":"e26246","DOI":"10.4161\/onci.26246","volume":"2","author":"AL Horenstein","year":"2013","unstructured":"Horenstein AL, Chillemi A, Zaccarello G et al (2013) A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2:e26246. https:\/\/doi.org\/10.4161\/onci.26246","journal-title":"Oncoimmunology"},{"key":"2820_CR12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3389\/fimmu.2017.01526","volume":"8","author":"MP de Andrade","year":"2017","unstructured":"de Andrade MP, Coutinho-Silva R, Savio LEB (2017) Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives. Front Immunol 8:1526. https:\/\/doi.org\/10.3389\/fimmu.2017.01526","journal-title":"Front Immunol"},{"key":"2820_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2012.04623.x","volume":"171","author":"FS Regateiro","year":"2013","unstructured":"Regateiro FS, Cobbold SP, Waldmann H (2013) CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol 171:1\u20137. https:\/\/doi.org\/10.1111\/j.1365-2249.2012.04623.x","journal-title":"Clin Exp Immunol"},{"key":"2820_CR14","doi-asserted-by":"publisher","first-page":"14711","DOI":"10.1073\/pnas.1308209110","volume":"110","author":"PA Beavis","year":"2013","unstructured":"Beavis PA, Divisekera U, Paget C et al (2013) Blockade of A 2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci 110:14711\u201314716. https:\/\/doi.org\/10.1073\/pnas.1308209110","journal-title":"Proc Natl Acad Sci"},{"key":"2820_CR15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hask\u00f3 G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13:842\u2013857. https:\/\/doi.org\/10.1038\/nrc3613","journal-title":"Nat Rev Cancer"},{"key":"2820_CR16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2217\/imt-2018-0200","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen S, Wainwright DA, Wu JD et al (2019) CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 11:983\u2013997. https:\/\/doi.org\/10.2217\/imt-2018-0200","journal-title":"Immunotherapy"},{"key":"2820_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"2820_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2017.136","volume":"117","author":"AP Cogdill","year":"2017","unstructured":"Cogdill AP, Andrews MC, Wargo JA (2017) Hallmarks of response to immune checkpoint blockade. Br J Cancer 117:1\u20137. https:\/\/doi.org\/10.1038\/bjc.2017.136","journal-title":"Br J Cancer"},{"key":"2820_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00315","volume":"8","author":"HT Marshall","year":"2018","unstructured":"Marshall HT, Djamgoz MBA (2018) Immuno-oncology: emerging targets and combination therapies. Front Oncol 8:1\u201329. https:\/\/doi.org\/10.3389\/fonc.2018.00315","journal-title":"Front Oncol"},{"key":"2820_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS et al (2016) Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30:391\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.025","journal-title":"Cancer Cell"},{"key":"2820_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","volume":"107","author":"J Stagg","year":"2010","unstructured":"Stagg J, Divisekera U, McLaughlin N et al (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci 107:1547\u20131552. https:\/\/doi.org\/10.1073\/pnas.0908801107","journal-title":"Proc Natl Acad Sci"},{"key":"2820_CR22","doi-asserted-by":"publisher","first-page":"8738","DOI":"10.18632\/oncotarget.14434","volume":"8","author":"Y Inoue","year":"2017","unstructured":"Inoue Y, Yoshimura K, Kurabe N et al (2017) Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget 8:8738\u20138751. https:\/\/doi.org\/10.18632\/oncotarget.14434","journal-title":"Oncotarget"},{"key":"2820_CR23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","volume":"30","author":"Y Kudo","year":"2019","unstructured":"Kudo Y, Haymaker C, Zhang J et al (2019) Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol 30:1521\u20131530. https:\/\/doi.org\/10.1093\/annonc\/mdz207","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2820_CR24","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","volume":"16","author":"LM Solis","year":"2010","unstructured":"Solis LM, Behrens C, Dong W et al (2010) Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16:3743\u20133753. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3352","journal-title":"Clin Cancer Res"},{"key":"2820_CR25","doi-asserted-by":"publisher","unstructured":"Rami-Porta R, Asamura H, Travis WD, Rusch VW (2017) Lung cancer-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:138\u2013155. https:\/\/doi.org\/10.3322\/caac.21390","DOI":"10.3322\/caac.21390"},{"key":"2820_CR26","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/cncr.26584","volume":"118","author":"LM Solis","year":"2012","unstructured":"Solis LM, Behrens C, Raso MG et al (2012) Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 118:2889\u20132899. https:\/\/doi.org\/10.1002\/cncr.26584","journal-title":"Cancer"},{"key":"2820_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mdw436","volume":"28","author":"H Kadara","year":"2017","unstructured":"Kadara H, Choi M, Zhang J et al (2017) Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol Off J Eur Soc Med Oncol 28:75\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdw436","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2820_CR28","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930\u20132940. https:\/\/doi.org\/10.1172\/JCI91190","journal-title":"J Clin Invest"},{"key":"2820_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523:231\u2013235. https:\/\/doi.org\/10.1038\/nature14404","journal-title":"Nature"},{"key":"2820_CR30","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24:1550\u20131558. https:\/\/doi.org\/10.1038\/s41591-018-0136-1","journal-title":"Nat Med"},{"key":"2820_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41598-019-57218-9","volume":"10","author":"S Hwang","year":"2020","unstructured":"Hwang S, Kwon A-Y, Jeong J-Y et al (2020) Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep 10:643. https:\/\/doi.org\/10.1038\/s41598-019-57218-9","journal-title":"Sci Rep"},{"key":"2820_CR32","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-19-2183","volume":"26","author":"B Sidders","year":"2020","unstructured":"Sidders B, Zhang P, Goodwin K et al (2020) Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response. Clin Cancer Res 26:2176\u20132187. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2183","journal-title":"Clin Cancer Res"},{"key":"2820_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","volume":"6","author":"P Danaher","year":"2018","unstructured":"Danaher P, Warren S, Lu R et al (2018) Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer 6:63. https:\/\/doi.org\/10.1186\/s40425-018-0367-1","journal-title":"J Immunother Cancer"},{"key":"2820_CR34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jmoldx.2019.04.011","volume":"21","author":"Z Qi","year":"2019","unstructured":"Qi Z, Wang L, Desai K et al (2019) Reliable gene expression profiling from small and hematoxylin and eosin-stained clinical formalin-fixed, paraffin-embedded specimens using the HTG edgeseq platform. J Mol Diagn 21:796\u2013807. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.04.011","journal-title":"J Mol Diagn"},{"key":"2820_CR35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Diao L, Yang Y et al (2018) CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-l1 blockade. Cancer Discov 8:1156\u20131175. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1033","journal-title":"Cancer Discov"},{"key":"2820_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","volume":"15","author":"S Lantuejoul","year":"2020","unstructured":"Lantuejoul S, Sound-Tsao M, Cooper WA et al (2020) PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. J Thorac Oncol 15:499\u2013519. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.107","journal-title":"J Thorac Oncol"},{"key":"2820_CR37","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1158\/1078-0432.CCR-15-2443","volume":"22","author":"ER Parra","year":"2016","unstructured":"Parra ER, Behrens C, Rodriguez-Canales J et al (2016) Image analysis-based assessment of pd-l1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clin Cancer Res 22:6278\u20136289. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2443","journal-title":"Clin Cancer Res"},{"key":"2820_CR38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jtho.2018.03.002","volume":"13","author":"ER Parra","year":"2018","unstructured":"Parra ER, Villalobos P, Zhang J et al (2018) Immunohistochemical and image analysis-based study shows that several immune checkpoints are co-expressed in non-small cell lung carcinoma tumors. J Thorac Oncol 13:779\u2013791. https:\/\/doi.org\/10.1016\/j.jtho.2018.03.002","journal-title":"J Thorac Oncol"},{"key":"2820_CR39","doi-asserted-by":"publisher","first-page":"e1208875","DOI":"10.1080\/2162402X.2016.1208875","volume":"5","author":"CM Hay","year":"2016","unstructured":"Hay CM, Sult E, Huang Q et al (2016) Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology 5:e1208875. https:\/\/doi.org\/10.1080\/2162402X.2016.1208875","journal-title":"Oncoimmunology"},{"key":"2820_CR40","unstructured":"NIH-U.S. National Library of Medicine (2019) ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/results?cond=Lung+Cancer&term=CD73&cntry=&state=&city=&dist=&Search=Search"},{"key":"2820_CR41","doi-asserted-by":"publisher","first-page":"6246493","DOI":"10.1155\/2018\/6246493","volume":"2018","author":"S Pervez","year":"2018","unstructured":"Pervez S, Arshad S, Abro B (2018) HER2 basolateral versus circumferential IHC expression is dependent on polarity and differentiation of epithelial cells in gastric\/GE adenocarcinoma. Patholog Res Int 2018:6246493. https:\/\/doi.org\/10.1155\/2018\/6246493","journal-title":"Patholog Res Int"},{"key":"2820_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","volume":"10","author":"S Vigano","year":"2019","unstructured":"Vigano S, Alatzoglou D, Irving M et al (2019) Targeting adenosine in cancer immunotherapy to enhance T-Cell function. Front Immunol 10:925. https:\/\/doi.org\/10.3389\/fimmu.2019.00925","journal-title":"Front Immunol"},{"key":"2820_CR43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Fan J, Zhang M et al (2019) CD73 expression on effector T cells sustained by TGF-\u03b2 facilitates tumor resistance to anti-4-1BB\/CD137 therapy. Nat Commun 10:150. https:\/\/doi.org\/10.1038\/s41467-018-08123-8","journal-title":"Nat Commun"},{"key":"2820_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","volume":"414","author":"F Teng","year":"2018","unstructured":"Teng F, Meng X, Kong L, Yu J (2018) Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: a systematic review. Cancer Lett 414:166\u2013173. https:\/\/doi.org\/10.1016\/j.canlet.2017.11.014","journal-title":"Cancer Lett"},{"key":"2820_CR45","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00285.2019","author":"M Minor","year":"2019","unstructured":"Minor M, Alcedo KP, Battaglia RA, Snider NT (2019) Cell type- and tissue-specific functions of ecto-5\u2019-nucleotidase (CD73). Am J Physiol Cell Physiol. https:\/\/doi.org\/10.1152\/ajpcell.00285.2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"2820_CR46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, Milenkovski N, Henderson MA et al (2015) Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 3:506\u2013517. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0211","journal-title":"Cancer Immunol Res"},{"key":"2820_CR47","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot I, Michaud H-A, Giraudon-Paoli M et al (2019) Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 27:2411-2425.e9. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.091","journal-title":"Cell Rep"},{"key":"2820_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2019.04.035","volume":"117","author":"L Mazzarella","year":"2019","unstructured":"Mazzarella L, Duso BA, Trapani D et al (2019) The evolving landscape of \u201cnext-generation\u201d immune checkpoint inhibitors: a review. Eur J Cancer 117:14\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.035","journal-title":"Eur J Cancer"}],"updated-by":[{"DOI":"10.1007\/s00262-021-02893-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02820-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02820-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02820-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T10:08:15Z","timestamp":1627639695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02820-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["2820"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02820-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00262-021-02893-9","asserted-by":"object"}]},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-021-02893-9","URL":"https:\/\/doi.org\/10.1007\/s00262-021-02893-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the MD Anderson Institutional Review Board and was conducted according to the principles of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}